Table 2.

METTL3 Expression in ESCC Patients by Kaplan–Meier Survival Analysis (Log Rank Test)

Variables	Cases	DFS (months)			OS (months)
		Mean	Median	p-value	Mean	Median	p-value
Total
Low expression	128	72.4	NR	<0.001*	74.9	NR	<0.001*
High expression	79	38.6	18		44	25
pT statusa
pT1-2
Low expression	39	66.5	NR	0.064	70.1	NR	0.057
High expression	14	42.3	30		48.5	54
pT3-4
Low expression	89	72.3	NR	<0.001*	74.1	NR	<0.001*
High expression	65	37.2	17		42.1	25
N categoriesa
N0
Low expression	75	86.4	NR	0.006*	88.1	NR	0.009*
High expression	35	58.6	58		63.2	66
N>0
Low expression	53	44.2	29	<0.001*	48.3	40	<0.001*
High expression	44	19.6	10		25.7	15
Histologic gradea
G1
Low expression	27	74.6	NR	0.002*	76.4	NR	0.002*
High expression	24	37.5	26		44	45
G2-3
Low expression	101	69.7	NR	<0.001*	72.4	74	<0.001*
High expression	55	38.1	14		43	25
TNM stagea
Stage I+II
Low expression	89	83	NR	0.02*	85.2	NR	0.025*
High expression	37	60	58
Stage III
Low expression	39	40	27	0.001*	43.2	39	0.002*
High expression	42	17.2	9		23.1	15

Notes: *p < 0.05, statistically significant; ^aThe grading and histopathology stage of ESCC specimens are based on the World Health Organization classification published in 2009.

Abbreviations: DFS, disease-free survival; ESCC, esophageal squamous cell carcinoma; G1, well differentiated; G2-3, moderately differentiated and poorly differentiated; METTL3, methyltransferase like 3; N categories, lymph node metastasis status; N0, lymph node metastasis negative; N>0, lymph node metastasis positive; NR, not reached; OS, overall survival; pT status, histopathology tumor status; TNM stage, tumor/node/metastasis staging classification.